2-氨基喹唑啉-4-羧基苯胺 | 1001326-03-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氨基喹唑啉-4-羧基苯胺
• 英文名称: 2-aminoquinazoline-4-carboxyanilide
• 英文别名: 2-amino-4-phenylcarbamoyl-quinazoline；2-amino-N-phenylquinazoline-4-carboxamide
• CAS: 1001326-03-9
• 化学式: C₁₅H₁₂N₄O
• 分子量: 264.286
• InChiKey: FXATZDLBKVHWOG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  80.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-氨基喹唑啉-4-羧基苯胺 、 苯甲酰氯 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 30.0h， 以80%的产率得到2-benzoylaminoquinazoline-4-carboxyanilide
  参考文献：
  名称：

  Scouting Human A₃ Adenosine Receptor Antagonist Binding Mode Using a Molecular Simplification Approach: From Triazoloquinoxaline to a Pyrimidine Skeleton as a Key Study

  摘要：

  The concept of molecular simplification as a drug design strategy to shorten synthetic routes, while keeping or enhancing the biological activity of the lead drug, has been applied to design new classes of human A(3) adenosine receptor (AR) antagonists. Over the past decade, we have focused a part of our research on the study of AR antagonists belonging to strictly correlated classes of tricyclic compounds. One of these classes is represented by the 2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives, either 4-amino or 4-oxosubstituted, which were intensively investigated by evaluating the effect of different substituents on the 2-phenyl ring and on the 4-amino group. Using an in silico molecular simplification approach, a new series of easily synthesizable 2-amino/2-oxoquinazoline-4-carboxamido derivatives have been discovered, presenting high affinity and selectivity against human A(3) AR.

  DOI：

  10.1021/jm070852a
• 作为产物：
  描述：

  2-氨基喹唑啉-4-羧酸 、 苯胺 在 4-二甲氨基吡啶 1-羟基苯并三唑 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 168.0h， 以54%的产率得到2-氨基喹唑啉-4-羧基苯胺
  参考文献：
  名称：

  Scouting Human A₃ Adenosine Receptor Antagonist Binding Mode Using a Molecular Simplification Approach: From Triazoloquinoxaline to a Pyrimidine Skeleton as a Key Study

  摘要：

  The concept of molecular simplification as a drug design strategy to shorten synthetic routes, while keeping or enhancing the biological activity of the lead drug, has been applied to design new classes of human A(3) adenosine receptor (AR) antagonists. Over the past decade, we have focused a part of our research on the study of AR antagonists belonging to strictly correlated classes of tricyclic compounds. One of these classes is represented by the 2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives, either 4-amino or 4-oxosubstituted, which were intensively investigated by evaluating the effect of different substituents on the 2-phenyl ring and on the 4-amino group. Using an in silico molecular simplification approach, a new series of easily synthesizable 2-amino/2-oxoquinazoline-4-carboxamido derivatives have been discovered, presenting high affinity and selectivity against human A(3) AR.

  DOI：

  10.1021/jm070852a

文献信息

• Quinazolinamide derivatives
  申请人：Eggenweiler Hans-Michael

  公开号：US20100234324A1

  公开（公告）日：2010-09-16

  Novel quinazolinamide derivatives of the formula (I), in which R 1 -R 3 have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.

  新型喹唑啉酰胺衍生物的化学式（I），其中R1-R3具有权利要求书中指示的含义，是HSP90抑制剂，可用于制备用于治疗HSP90在疾病的抑制、调节和/或调控中发挥作用的药物。
• Zur Behandlung von Tumorerkrankungen geeignete Chinazolinamidderivate
  申请人：Merck Patent GmbH

  公开号：EP2164833B1

  公开（公告）日：2015-04-15
• US8501754B2
  申请人：——

  公开号：US8501754B2

  公开（公告）日：2013-08-06
• Scouting Human A₃ Adenosine Receptor Antagonist Binding Mode Using a Molecular Simplification Approach: From Triazoloquinoxaline to a Pyrimidine Skeleton as a Key Study
  作者：Erika Morizzo、Francesca Capelli、Ombretta Lenzi、Daniela Catarzi、Flavia Varano、Guido Filacchioni、Fabrizio Vincenzi、Katia Varani、Pier Andrea Borea、Vittoria Colotta、Stefano Moro

  DOI：10.1021/jm070852a

  日期：2007.12.27

  The concept of molecular simplification as a drug design strategy to shorten synthetic routes, while keeping or enhancing the biological activity of the lead drug, has been applied to design new classes of human A(3) adenosine receptor (AR) antagonists. Over the past decade, we have focused a part of our research on the study of AR antagonists belonging to strictly correlated classes of tricyclic compounds. One of these classes is represented by the 2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives, either 4-amino or 4-oxosubstituted, which were intensively investigated by evaluating the effect of different substituents on the 2-phenyl ring and on the 4-amino group. Using an in silico molecular simplification approach, a new series of easily synthesizable 2-amino/2-oxoquinazoline-4-carboxamido derivatives have been discovered, presenting high affinity and selectivity against human A(3) AR.